Mar. 31, 2023

sparsentan

FIC oral, once-daily, dual ETA/AT1 antagonist FDA-approved for proteinuria reduction in primary IgAN opt. of known ETA/AT1 antagonist FDA accelerated approval, February 17, 2023 Travere Therapeutics, San Diego, CA

drughunter.com
Drug Hunter Team
Loading...

twitterlinkedinemail

Other molecules you may be interested in